Applications

1555 – Endoscopic Sleeve Gastroplasty (ESG) for the treatment of patients with Class I and Class II obesity with comorbidities who have failed first-line treatments

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Not supported

Application details

Reason for application

New MBS item.

Service or technology in this application

Endoscopic Sleeve Gastroplasty is an incisionless, minimally invasive procedure developed for bariatric treatment. ESG is delivered in a single endoscopic session using commercially available equipment. ESG reduces gastric capacity between 70% and 85% by creating a restrictive sleeve through a series of endoscopically placed full-thickness sutures. This imbrication of the greater curvature of the stomach is similar to but not identical to sleeve gastrectomy in shape. The gastroplasty is created using an endoscopic suturing device fitted to an endoscope. An oesophageal overtube is using during the procedure as well as a tissue helix device to ensure full-thickness bites. The procedure is performed under general anaesthesia with endotracheal intubation.

Type: Therapeutic

Medical condition this application addresses

According to the Australian Institute of Health and Welfare, 63% of Australian adults were overweight or obese in 2014-15 [1]. Of this population, 28% are obese, equating to roughly six million Australians with a body mass index (BMI) of 30 and above. Current studies show that around 70% of obese individuals have at least one established morbidity, including but not limited to type-2 diabetes, heart disease, sleep apnoea, hypertension, stroke, and musculoskeletal diseases [2]. Obesity has also been linked to various cancers and it is estimated that 3.6% of all new cancers globally are attributable to overweight and obesity [3]. From an economic perspective, obese individuals have medical costs that are roughly 30% greater than their normal weight peers [4]. The latest PricewaterhouseCoopers report estimated that the direct and indirect costs of obesity in Australia is $8.65 billion, creating a large financial burden on Australia’s healthcare system as well as tying up valuable healthcare resources to treat this chronic disease [5].

Application documents

Application form

Consultation survey

PICO confirmation

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: 6 to 7 December 2018
  • ESC meeting: 10 to 11 October 2019
  • MSAC meeting: 28 to 29 November 2019